Statin Therapy

ATLANTA — In this Healio video exclusive, Seth S. Martin, MD, MHS, FAHA, discusses research into lipid disorders from the American College of Cardiology Scientific Session, examining the TACTiC study on statin therapy.

ATLANTA — An investigational monthly PCSK9 inhibitor cut LDL cholesterol by more than 50% at 1 year among adults with CVD or with very high risk, in addition to background statin and ezetimibe therapy, researchers reported.

ATLANTA — New results from the TACTiC trial show the promise of technology to help individuals appropriately determine if they qualify for statin therapy without a prescription.

ATLANTA — For patients with atherosclerotic CVD, an inclisiran-first strategy was associated with greater lowering of LDL compared with the usual care, researchers reported at the American College of Cardiology Scientific Session.

The National Lipid Association issued a focused update on its 2019 scientific statement on use of lipoprotein(a) in clinical practice, incorporating new evidence into recommendations for managing patients with high Lp(a).

An HHS panel recommended this week that people with HIV begin taking a statin as young as age 40 years to lower their risk for a serious cardiac event, even if their risk for heart disease is in the low-to-moderate range.

Pharmacists are one of the most accessible health care providers and singularly well positioned to lead efforts in integrating pharmacogenomics testing to improve medication-related outcomes.

Researchers reported that a population-based study shows statin use among older adults with heart failure was associated with a 20% lower risk for all-cause dementia, including a 28% reduction in risk for developing Alzheimer’s disease.

Heart disease continues to be the leading cause of death and disability in the U.S. and worldwide. Atherosclerotic CVD, which is caused by plaque buildup in arterial walls, contributes to multiple life-threatening conditions.

The FDA approved a second pulsed field ablation system for the treatment of paroxysmal atrial fibrillation based on real-world data from the MANIFEST-17K registry and positive findings from the pivotal ADVENT clinical trial.